BEONE MEDICINES LTD. (ONC) Business News April 30, 2026, 16:03 UTC 米国FDA、一次治療のHER2陽性胃食道腺がん（GEA）に対するBeOne MedicinesのTEVIMBRAを優先審査の対象に指定 Full text
Register to leave comments News bot April 30, 2026, 4:17 p.m. 📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business
📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business